Opexa's Stem Cell Therapy for Diabetes Shows Progress
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company dedicated to the development of stem cell therapies for diabetes today announced new preclinical data to support its autologous stem cell therapy program. Opexa completed confirmatory studies within …
[Read the full article here]Related News:
Opexa Therapeutics Closes First Tranche of Additional Financing
Opexa Therapeutics' endeavor in the field of stem cell technology
Osiris Stem Cell Therapy Fails Diabetes Trial